Qiagen Stock Gains As Non COVID Sales Boosts Q2 Topline, Bottom-line

  • Qiagen N.V. QGEN reported after the close of the market Thursday that its second-quarter revenues jumped 28% Y/Y as growth in its core product portfolio tempered, flagging non-COVID-19-related sales.
  • It reported total revenues of $567.3 million, in line with preliminary numbers provided earlier this month and beating analysts' consensus estimate of $554.4 million. 
  • At constant exchange rates (CER), Q2 revenue growth was 24%.
  • Sales for non-COVID-related product groups rose 52% at CER to $407.6 million in Q2 and represented 72% of total sales. Meanwhile, COVID-19 product group sales declined 17% at CER to $159.7 million from a year ago as testing demand waned due to increased vaccination uptake.
  • Q2 consumables and related revenues grew 28% at CER to about $498 million, while instrument sales fell 3% at CER to $69 million. 
  • Sales of non-COVID-19 testing kits represented about two-thirds of the Sample technologies product group and rose nearly 30% at CER, buoying a double-digit year-over-year decline in kits used for COVID-19 testing.
  • Adjusted EPS of $0.66 beat the consensus of $.62.
  • Adjusted operating income increased 23% to $196.4 million, bit margin compressed to 34.6% from 36.1% a year ago.
  • Price Action: QGEN shares are up 2.26% at $53.40 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsLong IdeasNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!